T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Snap-25 is required for a late postdocking step in ca2+-dependent exocytosis
TL;DR: It is concluded that plasma membrane SNAP-25, particularly residues 181-197, is required for Ca2+-regulated membrane fusion at a step beyond LDCV docking and ATP utilization.
Journal ArticleDOI
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Ashraf Badros,Ravi Vij,Thomas Martin,Jeffrey A. Zonder,Lori Kunkel,Zhengping Wang,Susan Lee,Alvin F. Wong,Ruben Niesvizky +8 more
TL;DR: The pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilZomib was well tolerated and demonstrated promising efficacy.
Journal ArticleDOI
High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results.
Nikolaos Zamboglou,Nikolaos Tselis,Dimos Baltas,Thomas Buhleier,Thomas Martin,Natasa Milickovic,S. Papaioannou,Hanns Ackermann,Ulf W. Tunn +8 more
TL;DR: The authors' results confirm IRT-HDR-BRT is safe and effective as monotherapy for clinically localized prostate cancer.
Journal ArticleDOI
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Thomas Martin,Rachid Baz,Don M. Benson,Nikoletta Lendvai,Nikoletta Lendvai,Jeffrey L. Wolf,Pamela N. Munster,Alexander M. Lesokhin,Alexander M. Lesokhin,Claudine Wack,Eric Charpentier,Frank Campana,Ravi Vij +12 more
TL;DR: The data suggest that isatuximab combined with lenalidomide and dexamethasone is active and tolerated in heavily pretreated patients with RRMM.
Journal ArticleDOI
Stages of regulated exocytosis.
TL;DR: Progress in this direction from in vivo and in vitro studies that have characterized roles for specific proteins in post-docking steps proximal to membrane fusion is discussed.